Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
about
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersThe development of immunoconjugates for targeted cancer therapyGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerAdvances in anticancer immunotoxin therapyLoss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factorMechanisms of action of therapeutic antibodies for cancerNovel CD20 monoclonal antibodies for lymphoma therapyChemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.Removing T-cell epitopes with computational protein design.Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies.Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.Pediatric Rhabdomyosarcoma.Targeted diphtheria toxin to treat BPDCN.In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.Antibody phage display libraries: contributions to oncology.Update on the biology and treatment options for hairy cell leukemia.Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in micePhase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Characterization of CD22 expression in acute lymphoblastic leukemiaConstruction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.Advances in phage display technology for drug discovery.Improving access to novel agents for childhood leukemia.Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutationSelective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor CellsRecent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsImpact of telomere length on survival in classic and variant hairy cell leukemia.Immunoconjugates in the management of hairy cell leukemia.
P2860
Q26751473-690C905F-3108-4EAC-A6B3-95EEDDEF1DB9Q27021990-DD0BD294-C5D4-4E82-990C-7C769984C49AQ28077270-46DC149A-1331-4682-9186-E52947FEB85FQ28085551-B7D7EFB6-72A6-4F05-BC60-CE3BCE27FF30Q28266122-3065B476-D17B-43A4-9202-16B037611FD8Q28385366-944A5F76-F90E-479F-B520-97BBFE6B35EDQ28390112-39AFA599-588A-4200-878C-6D76018D084DQ28553712-BEC327D0-BB0B-4E79-ABE5-F1CFE95CBD38Q30362724-317CF7CC-6860-46D3-BD8B-853B6619696DQ33410756-351C6145-EF43-4ACC-B391-78B2D5880BC0Q33415933-33EB6050-4C2A-4459-A773-5E2A79FE25A5Q33652098-1D12224B-8BA1-4F9D-960D-D48A87DA1547Q33761496-1BC5D4F3-EF26-42F1-A48B-341A89FCBDECQ33767727-E632F034-7CC9-4D66-9F5A-D72A3C9C8FADQ33840201-349C0976-2038-4C3E-A25C-3B8F62A87132Q33842070-12CB693D-7E4B-46DB-B1F8-B1CFD024C176Q33917153-4C72A145-DB98-4A8A-BF4F-83EFEDBB4700Q34080906-116D2021-357F-4CA6-95DE-018A291F4B9AQ34276680-28896CD7-BA8A-4589-ACA4-92B88DB5D199Q34323838-024CDC4C-EEF7-452A-A8A8-4A2EB5C8FFC2Q34323991-3BE6ADDC-4430-43F8-BDB2-F3EE97F728B2Q34343369-CD9A1F15-8EB6-4EDE-8997-839911A53D54Q34385892-E7F1ABD4-5E21-400D-8F0E-533D5259CD51Q34387911-42F92755-5211-4408-A278-62656649E84AQ34459015-3102293C-4DE7-47BF-85F6-1B0AD600011BQ34459751-AEA5AE3D-38D7-409C-8A76-358445E76A3BQ35070412-97F5B803-CFC8-4027-8FC8-9B3618A4124EQ35180101-3E0F981F-1590-487B-B0F4-F1FBCE1FDF6DQ35514128-E4861220-12E1-4F6D-88F6-7F1ECFB2B79CQ35556641-9A193CAC-3229-4AEC-A710-987D15594464Q35614190-EE185091-F87C-47E7-BE4D-003940ECB064Q35688742-4F9261C0-E6BF-4449-A04B-EDFF5E23439BQ35876956-F632168C-934F-49CA-B8AB-15273D8BE3C8Q35992503-F178BBED-500A-4241-9748-93B33349B44AQ36069886-EB1B5AFC-AE10-4A48-BFCE-B81E329C2B46Q36157120-94AF8742-C792-47F7-AFB8-6DF50D65DED4Q36269852-D82B9D01-F266-4352-8D28-C18542CABAB8Q36273796-D9F07C52-9248-4E83-9918-79EC449E9373Q36322450-CD91631F-2E72-4B82-A22B-F355082F87EBQ36328016-6089C240-FCEF-41C5-97A9-5843A0F96DB3
P2860
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@ast
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@en
type
label
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@ast
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@en
prefLabel
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@ast
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@en
P2093
P2860
P356
P1476
Phase I trial of anti-CD22 rec ...... ents with hairy cell leukemia.
@en
P2093
David J Fitzgerald
Ira Pastan
Maryalice Stetler-Stevenson
Robert J Kreitman
Robert Lechleider
Steven Coutre
Tadeusz Robak
Wyndham H Wilson
P2860
P304
P356
10.1200/JCO.2011.38.1756
P407
P577
2012-02-21T00:00:00Z